Imperial Clinical Research Services Inc is categorized under Medical Labs in Langhorne, PA and active since 2001.
Imperial Clinical Research Services Inc was established in 2001, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Medical Labs business, which does work in the B2C market, and is classified as a Medical Labs, under code number 621511 by the NAICS.
If you are seeking more information, feel free to contact Bruce Bonney at the company’s single location by writing to 2270 Cabot Boulevard West # 400, Langhorne, Pennsylvania PA 19047 or by phoning (215) 757-9330. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
Business Name: | Imperial Clinical Research Services Inc |
Contact Person: | Bruce Bonney |
Address: | 2270 Cabot Boulevard West # 400, Langhorne, Pennsylvania 19047 |
Phone Number: | (215) 757-9330 |
Annual Revenue (USD): | $100.000 to $499.999 |
Founded: | 2001 |
Location Type: | Single Location |
Employee Number: | 1 to 4 |
Business Type: | B2C (Business to Consumer) |
Business Category: | Medical Labs |
SIC Code: | 8071 |
NAICS Code: | 621511 |
Share This Business: |
Imperial Clinical Research Services Inc was started in 2001 to provide professional Medical Labs under the SIC code 8071 and NAICS code 621511. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.
Feel free to contact Bruce Bonney for inquiries that concern Imperial Clinical Research Services Inc by calling the company number (215) 757-9330, as your correspondence is most welcome. Additionally, the physical location of the single location of Imperial Clinical Research Services Inc can be found at the coordinates as well as the street address 2270 Cabot Boulevard West # 400 in Langhorne, Pennsylvania 19047.
For its online presence, you may visit Imperial Clinical Research Services Inc’s website at and engage with its social media outlets through on Twitter and on Facebook.